Growth Hormone for Short Stature in Children with Chronic Kidney Disease

Children suffering from chronic kidney disease (CKD) frequently experience growth retardation and short stature, a condition often referred to as dwarfism. This is due to complex metabolic and hormonal imbalances that significantly impact their physical development and overall quality of life. While some interventions exist, there remains a critical need for effective and safe treatments to improve growth outcomes in these vulnerable patients before they undergo kidney transplantation.

As a Phase 3 study with an UNKNOWN status, specific efficacy and safety results are not yet publicly available. However, the study is meticulously designed to measure several key outcomes over 52 weeks and 104 weeks in its 68 estimated participants. The primary outcome is the change in height standard deviation score (ΔHT SDS), a standardized measure that quantifies growth improvement relative to age-matched healthy children. The most important anticipated finding is a significant increase in ΔHT SDS in the rhGH group compared to the control group, indicating improved linear growth. Secondary outcomes include growth velocity measured at 12 months and 24 months, bone maturation (bone age/chronological age: BA/CA ratio), and levels of IGF-1 (Insulin-like growth factor 1) SDS and IGF-1/IGFBP-3 molar ratio, all assessed at 12 months and 24 months. These comprehensive measures are expected to provide a detailed picture of rhGH treatment's impact on growth and key endocrine markers.